DIUPRES-250 (chlorothiazide; reserpine) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1958.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
DIUPRES-250 is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent) approved in 1958 for treating hypertension and heart failure. Chlorothiazide works by increasing sodium and chloride excretion in the distal renal tubule, while reserpine provides additional antihypertensive effects through sympathetic inhibition. The combination addresses multiple pathways in blood pressure regulation.
Approaching loss of exclusivity with minimal current market activity signals a shrinking brand team focused on transition planning and generic preparation rather than growth initiatives.
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Worked on DIUPRES-250 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DIUPRES-250 offers limited career growth due to its LOE-approaching status and minimal linked job openings; opportunities are concentrated in transition management, regulatory maintenance, and supply chain optimization rather than commercial expansion. This role is best suited for professionals seeking stable, operationally-focused positions in legacy brand management or those transitioning toward generic / biosimilar portfolio roles.